{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T19:21:21Z","timestamp":1777922481904,"version":"3.51.4"},"reference-count":4,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T00:00:00Z","timestamp":1771891200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Palliat Care"],"abstract":"<jats:p>In this letter, the authors evaluate the potential of suzetrigine, a newly U.S. Food and Drug Administration-approved selective NaV1.8 sodium channel inhibitor, as a novel nonopioid alternative for managing moderate-to-severe pain. By targeting peripheral sensory neurons and avoiding the central nervous system, suzetrigine offers a favorable safety profile that bypasses typical opioid-related risks such as respiratory depression, sedation, and tolerance. While clinical trials demonstrate its noninferiority to hydrocodone\/acetaminophen in acute postsurgical settings, the authors highlight significant barriers to its use in palliative and hospice care. These limitations include a lack of evidence in patients with serious illness, a current safety restriction of 14 days of use, and a high cost of approximately $15.50 per tablet. Consequently, while suzetrigine represents a significant pharmacological advancement, its current utility is likely limited to short-term acute pain crises until further data support its long-term application in serious illness management.<\/jats:p>","DOI":"10.1177\/08258597261427085","type":"journal-article","created":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T17:11:29Z","timestamp":1771953089000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Suzetrigine: A New Non-Opioid Analgesic Option With Potential Implications for Serious Illness Care"],"prefix":"10.1177","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2970-7910","authenticated-orcid":false,"given":"Ryan","family":"Baldeo","sequence":"first","affiliation":[{"name":"Stanford Health Care, Palo Alto, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Girish","family":"Swaminath","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Molly","family":"Svendsen","sequence":"additional","affiliation":[{"name":"Mayo Clinic Phoenix, AZ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2026,2,24]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.3390\/ddc4030032"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1097\/aln.0000000000005460"},{"key":"e_1_3_2_4_2","unstructured":"DailyMed\u2014JOURNAVX\u2014suzetrigine tablet film coated. U.S. National Library of Medicine. February 6 2025. Accessed August 18 2025. https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=f0976da4-1d20-4517-945c-b60ed2f41c12."},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.2147\/JPR.S509144"}],"container-title":["Journal of Palliative Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/08258597261427085","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/08258597261427085","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/08258597261427085","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T20:21:49Z","timestamp":1777666909000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/08258597261427085"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,24]]},"references-count":4,"alternative-id":["10.1177\/08258597261427085"],"URL":"https:\/\/doi.org\/10.1177\/08258597261427085","relation":{},"ISSN":["0825-8597","2369-5293"],"issn-type":[{"value":"0825-8597","type":"print"},{"value":"2369-5293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,24]]},"article-number":"08258597261427085"}}